WO1999046371A3 - Induction of apoptotic or cytotoxic gene expression by adenoviral mediated gene codelivery - Google Patents
Induction of apoptotic or cytotoxic gene expression by adenoviral mediated gene codelivery Download PDFInfo
- Publication number
- WO1999046371A3 WO1999046371A3 PCT/US1999/005359 US9905359W WO9946371A3 WO 1999046371 A3 WO1999046371 A3 WO 1999046371A3 US 9905359 W US9905359 W US 9905359W WO 9946371 A3 WO9946371 A3 WO 9946371A3
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- apoptotic
- induction
- codelivery
- cytotoxic
- gene expression
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4747—Apoptosis related proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/10011—Adenoviridae
- C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
- C12N2710/10341—Use of virus, viral particle or viral elements as a vector
- C12N2710/10343—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2830/00—Vector systems having a special element relevant for transcription
- C12N2830/008—Vector systems having a special element relevant for transcription cell type or tissue specific enhancer/promoter combination
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Genetics & Genomics (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Zoology (AREA)
- Biotechnology (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Medicinal Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Engineering & Computer Science (AREA)
- Wood Science & Technology (AREA)
- Biophysics (AREA)
- Biomedical Technology (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Virology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Microbiology (AREA)
- Plant Pathology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Physics & Mathematics (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Toxicology (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
Priority Applications (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CA002322663A CA2322663A1 (en) | 1998-03-11 | 1999-03-11 | Induction of apoptotic or cytotoxic gene expression by adenoviral mediated gene codelivery |
AU31837/99A AU762493B2 (en) | 1998-03-11 | 1999-03-11 | Induction of apoptic or cytotoxic gene expression by adenoviral mediated gene codelivery |
EP99913854A EP1070122A4 (en) | 1998-03-11 | 1999-03-11 | Induction of apoptic or cytotoxic gene expression by adenoviral mediated gene codelivery |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US7754198P | 1998-03-11 | 1998-03-11 | |
US60/077,541 | 1998-03-11 |
Publications (3)
Publication Number | Publication Date |
---|---|
WO1999046371A2 WO1999046371A2 (en) | 1999-09-16 |
WO1999046371A9 WO1999046371A9 (en) | 2000-02-17 |
WO1999046371A3 true WO1999046371A3 (en) | 2000-08-24 |
Family
ID=22138678
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US1999/005359 WO1999046371A2 (en) | 1998-03-11 | 1999-03-11 | Induction of apoptotic or cytotoxic gene expression by adenoviral mediated gene codelivery |
Country Status (4)
Country | Link |
---|---|
EP (1) | EP1070122A4 (en) |
AU (1) | AU762493B2 (en) |
CA (1) | CA2322663A1 (en) |
WO (1) | WO1999046371A2 (en) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN110174456B (en) * | 2019-06-11 | 2021-09-21 | 华润双鹤药业股份有限公司 | Method for measuring lung surfactant protein and application thereof |
Families Citing this family (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ATE412058T1 (en) * | 2000-03-24 | 2008-11-15 | Cell Genesys Inc | INTERNAL RIBOSOME ACCESS SITE-CONTAINING CELL-SPECIFIC ADENOVIRAL VECTORS |
US6875610B2 (en) | 2000-05-31 | 2005-04-05 | Human Gene Therapy Research Institute | Methods and compositions for efficient gene transfer using transcomplementary vectors |
WO2001093899A1 (en) * | 2000-06-02 | 2001-12-13 | Hiroshi Okamoto | PANCREATIC LANGERHANS β CELL PROLIFERATION PROMOTER AND APOPTOSIS INHIBITOR, AND SCREENING OF CANDIDATE COMPOUNDS FOR THE E DRUGS |
US6579522B1 (en) | 2000-06-27 | 2003-06-17 | Genvec, Inc. | Replication deficient adenoviral TNF vector |
EP1207205A1 (en) * | 2000-11-20 | 2002-05-22 | Crucell Holland B.V. | Adenoviral replicons |
US20030086903A1 (en) | 2001-11-02 | 2003-05-08 | Genvec, Inc. | Therapeutic regimen for treating cancer |
US7247700B2 (en) * | 2001-12-31 | 2007-07-24 | Dana Farber Cancer Institute, Inc. | BID polypeptides and methods of inducing apoptosis |
JP4511108B2 (en) | 2002-05-31 | 2010-07-28 | オンコリクス インコーポレイテッド | Human prolactin antagonist-angiogenesis inhibitor fusion protein |
CN100361710C (en) | 2004-06-07 | 2008-01-16 | 成都康弘生物科技有限公司 | Construction and application of oncolytic adenovirus recombinant of tumor cell specifically expressing immunoregulation factor GM-CSF |
US20080081354A1 (en) * | 2006-10-02 | 2008-04-03 | Cardiac Pacemakers, Inc. | Devices, vectors and methods for inducible ischemia cardioprotection |
WO2018093580A1 (en) | 2016-11-16 | 2018-05-24 | Amgen Inc. | Triazole pyridyl compounds as agonists of the apj receptor |
EP3704122B1 (en) | 2017-11-03 | 2021-09-01 | Amgen Inc. | Fused triazole agonists of the apj receptor |
WO2019213006A1 (en) | 2018-05-01 | 2019-11-07 | Amgen Inc. | Substituted pyrimidinones as agonists of the apj receptor |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU5297496A (en) * | 1995-02-17 | 1996-09-04 | Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The | Methods of preparation and use of recombinant adenoviral vectors |
DE19615803A1 (en) * | 1996-04-20 | 1997-10-23 | Boehringer Ingelheim Int | CELO virus |
WO2000015648A1 (en) * | 1998-09-10 | 2000-03-23 | The Uab Research Foundation | Adenoviral vector encoding pro-apoptotic bax gene and uses thereof |
-
1999
- 1999-03-11 AU AU31837/99A patent/AU762493B2/en not_active Ceased
- 1999-03-11 EP EP99913854A patent/EP1070122A4/en not_active Withdrawn
- 1999-03-11 CA CA002322663A patent/CA2322663A1/en not_active Abandoned
- 1999-03-11 WO PCT/US1999/005359 patent/WO1999046371A2/en active IP Right Grant
Non-Patent Citations (5)
Title |
---|
"ONE WAY TO KILL CANCER: GIVE IT A COLD", XP002917479, Retrieved from the Internet <URL:HTTP://WWW.CNN.COM> [retrieved on 19970522] * |
COLL J.L. ET AL: "Antitumor Activity of Bax and p53 Naked Gene Transfer in Lung Cancer: In Vitro and in Vivo Analysis", HUMAN GENE THERAPY, vol. 9, no. 14, 20 September 1998 (1998-09-20), pages 2063 - 2074, XP002917478 * |
SAKAKURA C. ET AL: "Overexpression of Bax Sensitizes Human Breast Cancer MCF-7 Cells to Radiation-Incuced Apoptosis", INT. J. CANCER, vol. 67, 3 July 1996 (1996-07-03), pages 101 - 105, XP002917476 * |
See also references of EP1070122A4 * |
VOGELBAUM M.A. ET AL: "Transfection of C6 Glioma Cells with the Bax Gene and Increased Sensitivity to Treatment with Cytosine Arabinoside", JOURNAL OF NEUROSURGERY, vol. 88, no. 1, January 1998 (1998-01-01), pages 99 - 105, XP002917477 * |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN110174456B (en) * | 2019-06-11 | 2021-09-21 | 华润双鹤药业股份有限公司 | Method for measuring lung surfactant protein and application thereof |
Also Published As
Publication number | Publication date |
---|---|
AU762493B2 (en) | 2003-06-26 |
EP1070122A4 (en) | 2004-11-10 |
AU3183799A (en) | 1999-09-27 |
WO1999046371A2 (en) | 1999-09-16 |
WO1999046371A9 (en) | 2000-02-17 |
CA2322663A1 (en) | 1999-09-16 |
EP1070122A2 (en) | 2001-01-24 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO1999046371A3 (en) | Induction of apoptotic or cytotoxic gene expression by adenoviral mediated gene codelivery | |
EP1017797A4 (en) | Non-primate lentiviral vectors and packaging systems | |
EP1315512A4 (en) | Adenoviral targeting and manipulation of immune system response using targeting peptides | |
IL159637A0 (en) | Methods for genetic modification of hematopoietic progenitor cells and uses of the modified cells | |
WO2001022990A3 (en) | Methods related to immunostimulatory nucleic acid-induced interferon | |
WO2000054813A3 (en) | Use of recombinant gene delivery vectors for treating or preventing diseases of the eye | |
HUP9902310A2 (en) | Complementary adenoviral vector systems and cell lines | |
WO2000073478A3 (en) | Recombinant adenoviral vectors expressing chimeric fiber proteins for cell specific infection and genome integration | |
WO2006027693A8 (en) | Tumor specific genes and variant rnas and uses thereof as targets for cancer therapy and diagnosis | |
WO1999033998A3 (en) | Regulatory dna sequences of the human catalytic telomerase sub-unit gene, diagnostic and therapeutic use thereof | |
WO1999064594A3 (en) | Genes and gene expression products that are differentially regulated in prostate cancer | |
IL141984A0 (en) | Akt nucleic acids, polypeptides, and uses thereof | |
DK0843731T3 (en) | Gene therapy adenovirus vectors | |
AU2164197A (en) | Recombinant adenoviral vectors for human tumour gene therapy | |
AU3209300A (en) | Combination therapy of cancer by the activation of co-stimulatory molecules expressed by immune cells and cytokines | |
ZA200202413B (en) | Cell-specific and/or tumor-specific promoter retargeting of herpes gamma 34.5 gene expression. | |
WO2001005435A3 (en) | Antisense therapy for hormone-regulated tumors | |
WO1999054447A3 (en) | Human nucleic acid sequences of bladder tumour tissue | |
WO1999021589A3 (en) | Use of vectors such as adenoviruses and/or adeno associated viruses and/or retroviruses and/or herpes simplex viruses and/or liposomes and/or plasmids as a vehicle for genetic information enabling mammal cells to produce agents for the treatment of bone pathologies | |
AU2913400A (en) | Mage-3 derived immunogenic peptides presented by mhc of class ii and the use thereof | |
WO2000006735A8 (en) | Interferon alpha hybrids | |
EP1593742A3 (en) | Recombinant adenoviral vectors expressing chimeric fiber proteins for cell specific infection | |
WO2000022136A3 (en) | Recombinant e1a deleted adenoviral vectors | |
AU2002246455A1 (en) | Fusion proteins for specific treatment of cancer and auto-immune diseases | |
CA2385872A1 (en) | Gene transfer in human lymphocytes using retroviral scfv cell targeting |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A2 Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A2 Designated state(s): GH GM KE LS MW SD SL SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
AK | Designated states |
Kind code of ref document: C2 Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: C2 Designated state(s): GH GM KE LS MW SD SL SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG |
|
COP | Corrected version of pamphlet |
Free format text: PAGES 1/17-17/17, DRAWINGS, REPLACED BY NEW PAGES 1/16-16/16; DUE TO LATE TRANSMITTAL BY THE RECEIVING OFFICE (WITH AN UPDATED VERSION OF THE PAMPHLET FRONT PAGE) |
|
REG | Reference to national code |
Ref country code: DE Ref legal event code: 8642 |
|
AK | Designated states |
Kind code of ref document: A3 Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A3 Designated state(s): GH GM KE LS MW SD SL SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG |
|
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
122 | Ep: pct application non-entry in european phase | ||
ENP | Entry into the national phase |
Ref document number: 2322663 Country of ref document: CA Ref country code: CA Ref document number: 2322663 Kind code of ref document: A Format of ref document f/p: F |
|
NENP | Non-entry into the national phase |
Ref country code: KR |
|
WWE | Wipo information: entry into national phase |
Ref document number: 31837/99 Country of ref document: AU |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1999913854 Country of ref document: EP |
|
REG | Reference to national code |
Ref country code: DE Ref legal event code: 8642 |
|
WWP | Wipo information: published in national office |
Ref document number: 1999913854 Country of ref document: EP |
|
WWG | Wipo information: grant in national office |
Ref document number: 31837/99 Country of ref document: AU |